Prostate Cancer Blog - malecare.org

Comparing (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) and (11)C-choline PET/CT in Prostate Cancer Relapse

There has been a lot of hype and confusion about what is the best contrast for prostate cancer PET/CT scans. The two newest contrasts; (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) and (11)C-choline both have their supporters and their detractors. To try and evaluate the efficacy differences between these two contrasts in men who have suffered a bio-chemical recurrence [...]

By Malecare|2016-03-22T12:09:28-04:00March 22nd, 2016|(18)F-FACBC, [11C] choline PET/CT, Advanced Prostate Cancer, Bio Chemical Recurrence, General Information, Imaging, Scanning Technology, Technology, Uncategorized, Understanding Advanced Prostate Cancer|0 Comments

Xtandi Vs Zytiga

The phase III trials for both Xtandi and Zytiga were similar. Both trials investigated men who progressed or died against placebo. Only 14% of men taking Xtandi during the trial progressed or died compared to 40% of the men in the placebo group. In the phase III trial of Zytiga 28% of the men [...]

By Malecare|2019-08-16T09:30:57-04:00March 18th, 2016|Advanced Prostate Cancer, Clinical Trials, Clinical Trials & Research, Disease Progression, Drugs & Treatments, enzalutamide, General Information, Survival, Uncategorized, Xtandi, Zytiga|8 Comments

PSA Decline After 4 Weeks of Abiraterone Suggests Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer

Since we have many new treatments for men with castrate resistant metastatic prostate cancer (mCRPC) (advanced prostate cancer) we need to develop earlier indicators of when a treatment might or might not be successful. A decline in prostate-specific antigen (PSA) is widely used to monitor treatment response, but it has not been validated as an [...]

By Malecare|2016-03-15T23:25:25-04:00March 15th, 2016|abiraterone acetate, Advanced Prostate Cancer, biomarkers, Clinical Trials & Research, Drugs & Treatments, PSA, survival, Survival, Uncategorized, Understanding Advanced Prostate Cancer, United Kingdom - England, Northern Ireland, Scotland & Wales, Zytiga|1 Comment

What is the Actual Clinical Benefit of Using Low Dose Prednisone Along with Prostate Cancer Chemotherapy with Docetaxel?

Randomized trials have clearly demonstrated that when low dose Prednisone (P) is combined with docetaxel chemotherapy (D) to treat prostate cancer there is a survival benefit. What is the role of the prednisone and does it actually provide any additional benefit to the docetaxel treatment itself? To answer this question a retrospective study was performed [...]

By Malecare|2017-10-19T10:46:36-04:00March 15th, 2016|Advanced Prostate Cancer, Chemotherapy, Clinical Trials & Research, Combination Therapy, docetaxel, Drugs & Treatments, edema, Hospitalization, Research, Side Effects, Survival, Uncategorized, Understanding APC|0 Comments

A Small Analysis of Abiraterone Responses in African American Men with Metastatic Castration Resistant Prostate Cancer

Presented at ASCO GU by Stolten and colleagues was abstract 244 that described the responses African American men had to abiraterone (Zytiga) in a retrospective cohort study of men seen at a single institution. Stolten included differences in the men including their age at diagnosis, prior enzalutamide (Xtandi) and/or docetaxel (chemotherapy) use, as well as [...]

By Malecare|2020-02-04T10:22:29-05:00March 12th, 2016|abiraterone acetate, Advanced Prostate Cancer, Disease Progression, disparities, Disparities, Drugs & Treatments, Research, Uncategorized, Zytiga|0 Comments